Skip to main content
OpenTrials
Completed

NCT Number: NCT01335386

Investigation of KLYX in Patients With Constipation

This is a randomised, assessor-blind, multi-centre pilot study to investigate the comparative safety and efficacy of KLYX and glycerine enema in the symptomatic treatment of constipation in Chinese patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Changhai Hospital, The Second Military Medical University, Shanghai, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have signed the informed consent form and have been verbally explained the details of the trial and treatment procedures
  • Ethnically Chinese
  • Males or females aged between 18 and 65 years inclusive
  • A history of constipation symptoms for at least 6 months fulfilling, with occurrence of two or more of the following symptoms during the 3 months before screening (the 3 months need not be consecutive):

i. Very hard (pellet-like) and/or hard stools (Type 1 or 2 of the Bristol Stool Scale) for at least 25% of the time; or ii. Sensation of incomplete evacuation at least 25% of the time; or iii. Straining during defecation at least 25% of the time; or iv. Sensation of anorectal obstruction or blockage often during defecation at least 25% of the time; or v. Manual manoeuvres needed often to facilitate defecations (e.g. digital evacuation, support of the pelvic floor) at least 25% of the time; or vi. Fewer than 3 defecations per week.

  • Patient has had no bowel movement (i.e. still constipated) two days prior randomisation.

Exclusion criteria

  • Any disorder or laboratory result at Screening that in the judgement of the investigator that will place the subject at excessive risk if participating in a controlled study
  • Clinically suspected to have colorectal cancer
  • Significant gastroparesis or gastric outlet obstruction
  • Hypersensitivity to sodium docusate and/or sorbitol
  • Hypersensitivity to glycerine
  • Pregnant or lactating women, women who intend to conceive, or women who are sexually active and capable of pregnancy who are not using a method of birth control (e.g. prescription hormonal contraceptives, intrauterine device, double-barrier method, male partner sterilization)
  • Diabetic patients currently on insulin therapy
  • Having participated in other clinical trial(s) within the 3 (three) months prior screening
  • Unable to withdraw medications that may affect gastrointestinal motility such as prokinetics, erythromycin analogues, laxatives, etc.
  • Unable to meet or perform study requirements: known or suspected inability to comply with the study protocol

Treatment and study plan

KLYX

Drug

Glycerine

Drug

Primary outcomes

  1. Overall efficacy of enema

    Time frame: immediately following enema administration

Secondary outcomes

  1. Time to first bowel movement

    Time frame: Immediately following enema administration

  2. Patient's overall satisfaction with enema treatment

    Time frame: Immediately following enema administration

  3. Stool form after enema treatment

    Time frame: Immediately following enema administration

Sponsors and collaborators

Lead sponsor

Ferring Pharmaceuticals

Industry

Registry information

Official study title

Efficacy and Safety of KLYX Versus Glycerine Enema in Chinese Patients With Constipation - a Randomised, Assessor-blind Pilot Study

Important dates

Study start
2010
Primary completion
2010
Study completion
2010
First posted
Apr 14, 2011
Registry last updated
Feb 6, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.